Hematologic Disorders Education Center

Hematological disorders present an enormous set of challenges for clinicians. Healthcare providers are thankful that the treatment alternatives for these disorders are improving at a significant rate and that patient outcomes are improving as well.

The challenge for many clinicians is to keep track of the new pharmacologic approaches to treating hematological disorders. This website has been designed as a resource center for hematologists, oncologists, and other healthcare providers who are involved in the care of these patients.

Novel Targeted Leukemia Treatment Improves Survival

Novel Targeted Leukemia Treatment Improves Survival

According to research presented at AACR 2019, the FLT3 inhibitor gilteritinib successfully increased overall survival compared to chemotherapy, in patients with relapsed or refractory acute myeloid leukemia...
Older Age No Barrier to Ruxolitinib Use for Myelofibrosis

Older Age No Barrier to Ruxolitinib Use for Myelofibrosis

While 60% of cases of myelofibrosis occurs in individuals over age 65 and the proportion of patients affected by the disease continues to rise with age, no studies had analyzed how well older patients responded to ruxolitinib...
Better Lymphoma Outcomes with Bendamustine-Rituximab Combination

Better Lymphoma Outcomes with Bendamustine-Rituximab Combination

The combination of bendamustine and rituximab provides better progression-free survival (PFS), event-free survival, and duration of response in patients with indolent non-Hodgkin lymphoma and mantle-cell lymphoma...
Dose Escalation Mitigates Anemia in Myelofibrosis

Dose Escalation Mitigates Anemia in Myelofibrosis

Dose escalation upfront may reduce the need for dose reduction during ruxolitinib therapy for myelofibrosis...
FDA Grants Priority Review to Fedratinib for Myelofibrosis

FDA Grants Priority Review to Fedratinib for Myelofibrosis

The FDA has accepted the New Drug Application and granted a Priority Review for fedratinib for the treatment of patients with myelofibrosis...

Loading...